Found: 3
Select item for more details and to access through your institution.
Exploring the feasibility of using the ICER Evidence Rating Matrix for Comparative Clinical Effectiveness in assessing treatment benefit and certainty in the clinical evidence on orphan therapies for paediatric indications.
- Published in:
- Orphanet Journal of Rare Diseases, 2023, v. 18, n. 1, p. 1, doi. 10.1186/s13023-023-02701-w
- By:
- Publication type:
- Article
Cost-Effectiveness Analysis of Siltuximab for Australian Public Investment in the Rare Condition Idiopathic Multicentric Castleman Disease.
- Published in:
- PharmacoEconomics - Open, 2023, v. 7, n. 5, p. 777, doi. 10.1007/s41669-023-00426-x
- By:
- Publication type:
- Article
Internal Psychometric Validation of an International Burden of Illness Survey for Idiopathic Multicentric Castleman Disease.
- Published in:
- Oncology & Therapy, 2024, v. 12, n. 3, p. 491, doi. 10.1007/s40487-024-00293-4
- By:
- Publication type:
- Article